0.3403

5.68% 0.0183

Iterum Therapeutics Plc (ITRM)

Overview News Price History Financials Why ITRM Down? Discussions Forecast Stock Split

Iterum Therapeutics Plc stock is traded at $0.3403, with a volume of 293.52K. It is up +5.68% in the last 24 hours and down -15.35% over the past month. Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.

Previous Close:

$0.322

Open:

$0.33

24h Volume:

293.52K

Relative Volume:

0.31

Market Cap:

$18.14M

Revenue:

Net Income/Loss:

$-24.08M

P/E Ratio:

-0.397

EPS:

-0.8572

Net Cash Flow:

$-14.75M

1W Performance:

+3.75%

1M Performance:

-15.35%

6M Performance:

-64.92%

1Y Performance:

-77.90%

1-Day Range:

$0.322

$0.3499

1-Week Range:

$0.3105

$0.3499

52-Week Range:

$0.26

$1.75

Iterum Therapeutics Plc Stock (ITRM) Company Profile

Name

Iterum Therapeutics Plc

Sector

Healthcare (1115)

Industry

Biotechnology (624)

Phone

(872) 225-6077

Address

3 DUBLIN LANDINGS, DUBLIN 1

Employee

Twitter

Next Earnings Date

2025-02-07

Latest SEC Filings

ITRM's Discussions on Twitter

Compare ITRM with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ITRM Iterum Therapeutics Plc	0.3403	17.16M	0	-24.08M	-14.75M	-0.8572
VRTX Vertex Pharmaceuticals Inc	441.36	111.36B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	733.04	77.98B	14.25B	4.58B	3.88B	41.77
ARGX Argen X Se Adr	800.01	50.33B	3.06B	1.28B	447.35M	19.67
ALNY Alnylam Pharmaceuticals Inc	359.27	47.46B	3.21B	43.57M	221.36M	0.2405
ONC Beone Medicines Ltd Adr	338.19	37.43B	4.98B	69.59M	525.67M	0.5197

Iterum Therapeutics Plc Stock (ITRM) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
May-28-21	Upgrade	Gabelli & Co	Sell → Hold
Mar-15-21	Upgrade	H.C. Wainwright	Neutral → Buy
Jun-02-20	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Jan-21-20	Downgrade	Gabelli & Co	Buy → Sell
Dec-11-19	Downgrade	SVB Leerink	Outperform → Mkt Perform
Jun-21-19	Initiated	H.C. Wainwright	Buy

View All

Iterum Therapeutics Plc Stock (ITRM) Latest News

Jan 17, 2026

Weekly Earnings: How does Hovnanian Enterprises Inc compare to its peersRate Cut & Real-Time Price Movement Reports - baoquankhu1.vn

Jan 17, 2026

Jan 16, 2026

Activity Recap: What are the future prospects of Iterum Therapeutics plcMarket Sentiment Report & Fast Gaining Stock Reports - baoquankhu1.vn

Jan 16, 2026

Jan 13, 2026

Patterns Watch: Is Iterum Therapeutics plc stock a safe haven assetLayoff News & Low Risk Entry Point Tips - Bộ Nội Vụ

Jan 13, 2026

Jan 10, 2026

Will Iterum Therapeutics plc stock benefit from green energy trendsJuly 2025 Earnings & Daily Profit Focused Screening - Улправда

Jan 10, 2026

Jan 08, 2026

Is Iterum Therapeutics plc stock overvalued by current metricsProfit Target & High Return Trade Opportunity Guides - ulpravda.ru

Jan 08, 2026

Will Iterum Therapeutics plc stock benefit from sector rotationInflation Watch & Safe Capital Growth Stock Tips - Улправда

Jan 08, 2026

Can Iterum Therapeutics plc stock deliver surprise earnings beatWeekly Trade Report & Expert Curated Trade Setup Alerts - Улправда

Jan 08, 2026

Jan 07, 2026

Why Iterum Therapeutics plc stock remains a top recommendationStock Buyback Updates & Market Monitoring and Alerts - Улправда

Jan 07, 2026

Dec 23, 2025

Iterum Therapeutics expands market access for ORLYNVAH antibiotic - Investing.com

Dec 23, 2025

Iterum Therapeutics provides business update - marketscreener.com

Dec 23, 2025

Iterum Therapeutics Provides Business Update - The Manila Times

Dec 23, 2025

New antibiotic ORLYNVAH could reach 34M+ people pending FDA feedback - Stock Titan

Dec 23, 2025

Dec 19, 2025

Analyzing Iterum Therapeutics (NASDAQ:ITRM) & Savara (NASDAQ:SVRA) - Defense World

Dec 19, 2025

Dec 18, 2025

Why hedge funds are buying Iterum Therapeutics plc stockWeekly Trade Analysis & Capital Efficient Trade Techniques - Улправда

Dec 18, 2025

Dec 17, 2025

Iterum Therapeutics secures major PBM agreement for antibiotic By Investing.com - Investing.com Nigeria

Dec 17, 2025

Iterum Therapeutics (ITRM) Secures Key PBM Agreement and Expands Patent Portfolio - GuruFocus

Dec 17, 2025

Iterum Therapeutics secures major PBM agreement for antibiotic - Investing.com

Dec 17, 2025

New PBM deal could open ORLYNVAH access to 40M more people in 2026 - Stock Titan

Dec 17, 2025

Dec 14, 2025

Iterum Therapeutics faces Nasdaq listing compliance challenge - MSN

Dec 14, 2025

Dec 13, 2025

Iterum Therapeutics Faces Nasdaq Listing Compliance Challenge - The Globe and Mail

Dec 13, 2025

Iterum Therapeutics receives Nasdaq notice on listing compliance By Investing.com - Investing.com Australia

Dec 13, 2025

Dec 12, 2025

Iterum Therapeutics plc Stock Analysis and ForecastEarnings Forecast Updates & Fast Profit Stock Ideas - earlytimes.in

Dec 12, 2025

Iterum Therapeutics receives Nasdaq notice on listing compliance - Investing.com

Dec 12, 2025

Iterum Therapeutics (NASDAQ: ITRM) discloses Nasdaq delisting risk on value, price - Stock Titan

Dec 12, 2025

Dec 09, 2025